EP4384201A4 - Method for reducing the production of IGA, IGM and/or IGG using SBCMA variants and FC fusion proteins thereof - Google Patents

Method for reducing the production of IGA, IGM and/or IGG using SBCMA variants and FC fusion proteins thereof

Info

Publication number: EP4384201A4
Authority: EP; European Patent Office
Prior art keywords: sbcma; iga; igm; igg; variants
Prior art date: 2021-08-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP22856825.9A

Other languages

German (de)

French (fr)

Other versions

EP4384201A2 (en

Inventor

Amato J Giaccia

Yu Miao

Xin Eric Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Akso Biopharmaceutical Inc

Original Assignee

Akso Biopharmaceutical Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2021-08-11

Filing date

2022-08-11

Publication date

2025-07-30

2022-08-11 Application filed by Akso Biopharmaceutical Inc filed Critical Akso Biopharmaceutical Inc

2024-06-19 Publication of EP4384201A2 publication Critical patent/EP4384201A2/en

2025-07-30 Publication of EP4384201A4 publication Critical patent/EP4384201A4/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP22856825.9A 2021-08-11 2022-08-11 Method for reducing the production of IGA, IGM and/or IGG using SBCMA variants and FC fusion proteins thereof Pending EP4384201A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US202163232124P	2021-08-11	2021-08-11
PCT/US2022/074868 WO2023019223A2 (en)	2021-08-11	2022-08-11	METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Publications (2)

Publication Number	Publication Date
EP4384201A2 EP4384201A2 (en)	2024-06-19
EP4384201A4 true EP4384201A4 (en)	2025-07-30

Family

ID=85200996

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP22856825.9A Pending EP4384201A4 (en)	2021-08-11	2022-08-11	Method for reducing the production of IGA, IGM and/or IGG using SBCMA variants and FC fusion proteins thereof

Country Status (7)

Country	Link
EP (1)	EP4384201A4 (en)
JP (1)	JP2024529128A (en)
KR (1)	KR20240053675A (en)
CN (1)	CN118678963A (en)
AU (1)	AU2022327178A1 (en)
CA (1)	CA3228678A1 (en)
WO (1)	WO2023019223A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000040716A2 (en) *	1999-01-07	2000-07-13	Zymogenetics, Inc.	Soluble receptor br43x2 and methods of using them for therapy
AU2005200008A1 (en) *	1999-01-07	2005-01-27	Zymogenetics, Inc.	Soluble receptor BR43x2 and methods of using
WO2008119042A2 (en) *	2007-03-27	2008-10-02	Zymogenetics, Inc.	Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
US20110110943A1 (en) *	1999-01-07	2011-05-12	Zymogenetics, Inc.	Soluble receptor br43x2 and methods of using
WO2012163805A1 (en) *	2011-05-27	2012-12-06	Glaxo Group Limited	Bcma (cd269/tnfrsf17) -binding proteins
EP4146683A1 (en) *	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April and baff inhibitory immunomodulatory proteins and methods of use thereof
EP4196164A1 (en) *	2020-08-12	2023-06-21	The Board of Trustees of the Leland Stanford Junior University	Sbcma variants and fc fusion proteins thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9812634A (en)	1997-09-12	2000-08-22	Biogen Inc	April - a protein with growth effects
EP1028306B1 (en)	1998-08-28	2008-10-15	Mitutoyo Corporation	Apparatus and method concerning analysis and generation of a part program for measuring coordinates and surface properties
PL211786B1 (en)	1999-08-17	2012-06-29	Apoxis Sa	Application of an antibody and a polypeptide
UA74798C2 (en)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
RU2006117324A (en) *	2003-10-20	2007-12-10	Байоджен Айдек Ма Инк. (Us)	THERAPEUTIC MODES FOR BAFF ANTAGONISTS
UA112434C2 (en) *	2011-05-27	2016-09-12	Ґлаксо Ґруп Лімітед	ANTIGENCY BINDING SPECIFICALLY Binds to ALL
US20220235360A1 (en) *	2019-06-04	2022-07-28	Inserm (Institut National De La Santé Et De La Recherche Médecale)	Methods for modulating immunoglobulin expression

2022
- 2022-08-11 EP EP22856825.9A patent/EP4384201A4/en active Pending
- 2022-08-11 JP JP2024508471A patent/JP2024529128A/en active Pending
- 2022-08-11 CN CN202280067600.2A patent/CN118678963A/en active Pending
- 2022-08-11 AU AU2022327178A patent/AU2022327178A1/en active Pending
- 2022-08-11 CA CA3228678A patent/CA3228678A1/en active Pending
- 2022-08-11 WO PCT/US2022/074868 patent/WO2023019223A2/en not_active Ceased
- 2022-08-11 KR KR1020247007973A patent/KR20240053675A/en active Pending

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000040716A2 (en) *	1999-01-07	2000-07-13	Zymogenetics, Inc.	Soluble receptor br43x2 and methods of using them for therapy
AU2005200008A1 (en) *	1999-01-07	2005-01-27	Zymogenetics, Inc.	Soluble receptor BR43x2 and methods of using
US20110110943A1 (en) *	1999-01-07	2011-05-12	Zymogenetics, Inc.	Soluble receptor br43x2 and methods of using
WO2008119042A2 (en) *	2007-03-27	2008-10-02	Zymogenetics, Inc.	Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
WO2012163805A1 (en) *	2011-05-27	2012-12-06	Glaxo Group Limited	Bcma (cd269/tnfrsf17) -binding proteins
EP4146683A1 (en) *	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April and baff inhibitory immunomodulatory proteins and methods of use thereof
EP4196164A1 (en) *	2020-08-12	2023-06-21	The Board of Trustees of the Leland Stanford Junior University	Sbcma variants and fc fusion proteins thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023019223A2 *

Also Published As

Publication number	Publication date
AU2022327178A1 (en)	2024-03-28
WO2023019223A3 (en)	2023-09-28
CN118678963A (en)	2024-09-20
WO2023019223A2 (en)	2023-02-16
KR20240053675A (en)	2024-04-24
EP4384201A2 (en)	2024-06-19
JP2024529128A (en)	2024-08-01
CA3228678A1 (en)	2023-02-16

Legal Events

Date	Code	Title	Description
2023-02-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2024-05-17	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2024-05-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2024-06-19	17P	Request for examination filed	Effective date: 20240301
2024-06-19	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-11-20	DAV	Request for validation of the european patent (deleted)
2024-11-20	DAX	Request for extension of the european patent (deleted)
2025-01-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40111707 Country of ref document: HK
2025-07-30	A4	Supplementary search report drawn up and despatched	Effective date: 20250702
2025-07-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/17 20060101AFI20250626BHEP Ipc: A61P 37/06 20060101ALI20250626BHEP Ipc: C07K 14/715 20060101ALI20250626BHEP Ipc: C07K 16/46 20060101ALI20250626BHEP Ipc: C07K 19/00 20060101ALI20250626BHEP
2026-05-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

Publication	Publication Date	Title
DK4232463T3 (en)	2025-10-20	INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE
EP3714319C0 (en)	2024-11-13	SYSTEM AND METHOD FOR USING GAZE TRACKING AND FOCAL POINT TRACKING
EP3612930C0 (en)	2024-12-25	SYSTEM AND METHOD FOR IMPLEMENTING VARIOUS TYPES OF BLOCKCHAIN CONTRACTS
EP4030897A4 (en)	2023-10-18	T-CELL MODULATING POLYPEPTIDES AND METHOD OF USE THEREOF
EP3565828A4 (en)	2020-11-11	SIRP1-ALPHA-41BBL FUSION PROTEIN AND METHOD OF USING THEREOF
EP4408897A4 (en)	2025-10-15	ANTIGEN-BINDING POLYPEPTIDES, ANTIGEN-BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF
EP4021498A4 (en)	2024-01-03	CROSS-SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
DK4073098T5 (en)	2024-07-22	Ultra-long-acting insulin-Fc fusion proteins and methods of use
EP3935086A4 (en)	2022-11-23	CD93-SPECIFIC THERAPEUTIC ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
EP4181995A4 (en)	2025-05-07	SYSTEM AND METHOD FOR CONCENTRATING GAS
EP3857860C0 (en)	2023-10-18	SYSTEM AND METHOD FOR DISAMBIGUING INTERNET OF THINGS DEVICES
EP4100433A4 (en)	2024-03-13	METHOD FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES
EP4061848A4 (en)	2024-03-20	ANTI-ROR-2 ANTIBODIES AND METHOD OF USE
EP4031188A4 (en)	2023-11-01	RADIOM LABELING OF ANTI-CD45 IMMUNOGLOBULIN AND METHOD OF USE THEREOF
EP4401764A4 (en)	2025-11-05	ANTI-SIGLEC-6 ANTIBODIES AND METHOD FOR USE THEM
EP4055535A4 (en)	2023-11-01	SYSTEM AND METHOD FOR AUTHENTICATION OF HANDBAGS
EP4006667A4 (en)	2023-08-02	SYSTEM AND METHOD FOR GENERATION OF NC PROGRAMS
EP3870193C0 (en)	2025-10-08	SYSTEM AND METHOD FOR DETERMINING THE DEAMIDATION AND IMMUNOGENICITY OF POLYPEPTIDS
EP4449030C0 (en)	2026-01-21	METHOD FOR MEASURING HELIOSTATS AND METHOD FOR CALIBRINGING HELIOSTATS
EP4007606A4 (en)	2023-09-27	METHOD FOR ADMINISTRATION OF ANTI-SIGLEC-8 ANTIBODIES AND CORTICOSTEROIDS
EP4579453A4 (en)	2025-12-31	METHOD, SYSTEM AND NODE FOR THE PRODUCTION OF CONTAINERS
EP3946471C0 (en)	2024-05-15	POROUS HOLLOW FIBER MEMBRANE AND METHOD OF USING IT FOR SELECTING IMMUNE CHECKPOINT INHIBITOR
EP4086783A4 (en)	2024-02-07	METHOD AND SYSTEM FOR GENERATING ELECTRONIC HORIZONS
EP4326780A4 (en)	2025-02-26	ANTI-GPC3 ANTIBODIES, MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
EP3920956A4 (en)	2022-11-16	METHODS OF USE OF GLYCOSYLATED THERAPEUTIC PROTEINS